Niagen (NAGE) Soars 5.33% on Clinical Network Expansion

Niagen (NAGE) surged to a record high today, with an intraday gain of 5.33%.

The strategy of buying NAGE shares after they reached a recent high and holding for 1 week yielded moderate returns over the past 5 years. The annualized return was 16.19%, slightly underperforming the market benchmark. With a final value of $214.82, the strategy showed the effectiveness of holding onto NAGE shares post-high, although the overall performance was somewhat muted.

Niagen Bioscience has expanded its clinical network by making its pharmaceutical-grade Niagen® IV available in nearly 600 clinics nationwide. This expansion is a significant step in increasing the accessibility of their products, which could drive further growth in the company's revenue and market presence.

Additionally, the company has demonstrated robust financial performance, with a 37.41% increase in revenue over the recent three-month period as of December 31, 2024. This substantial growth indicates strong market demand and effective execution of the company's business strategies, which are likely contributing to the positive sentiment surrounding Niagen's stock.